Cargando…

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review

Atopic dermatitis (AD) is a common skin condition characterized by inflammation that presents with erythematous and pruritic skin. Its chronic relapse-remitting nature has a significant impact on the quality of life, and often requires ongoing management. Given the limited treatments available for A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lytvyn, Yuliya, Mufti, Asfandyar, Abduelmula, Abrahim, Sachdeva, Muskaan, Maliyar, Khalad, Georgakopoulos, Jorge R., Yeung, Jensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698998/ https://www.ncbi.nlm.nih.gov/pubmed/36432643 http://dx.doi.org/10.3390/pharmaceutics14112452

Ejemplares similares

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2022)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Reply to: “Skin damage among health care workers managing coronavirus disease 2019”
por: Maliyar, Khalad, et al.
Publicado: (2020)

Modifications to dermatology residency education during the COVID-19 pandemic
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Hereditary haemorrhagic telangiectasia: A case report
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

COVID-19 and wound care: A Canadian perspective
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review
por: Sachdeva, Muskaan, et al.
Publicado: (2021)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

34223 Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: A multicenter retrospective cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2023)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Dermatology: how to manage atopic dermatitis in patients with skin of colour
por: Sachdeva, Muskaan, et al.
Publicado: (2022)

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
por: Chiricozzi, Andrea, et al.
Publicado: (2022)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
por: Seale, Emily, et al.
Publicado: (2023)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

32414 Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: A multicentre retrospective cohort study
por: Rankin, Brian D., et al.
Publicado: (2022)

Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2020)

Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
por: De Greef, Axel, et al.
Publicado: (2023)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Optimizing care for atopic dermatitis patients during the COVID-19 pandemic
por: Shah, Monica, et al.
Publicado: (2020)

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_76v8ulgebgao0serq4n62ekjpe